Fungizone For Tissue Culture (amphotericin b) Disease Interactions
There is 1 disease interaction with Fungizone For Tissue Culture (amphotericin b):
Ampho B (Includes Fungizone For Tissue Culture) ↔ Anemia
Moderate Potential Hazard, High plausibility
Applies to: Anemia
Intravenous amphotericin B therapy may depress erythropoietin and red blood cell production and commonly causes a normocytic, normochromic anemia. Although the anemia is well tolerated by most patients and usually reverses completely within several months of stopping therapy, it may be problematic in patients with preexisting anemia. Intravenous therapy with amphotericin B should be administered cautiously in anemic patients or those predisposed to anemia. Frequent monitoring of blood counts and hemoglobin concentrations are recommended.
- "Amphotericin." Med Lett Drugs Ther 30 (1988): 30-2
- Miller R, Bates J "Amphotericin B toxicity." Ann Intern Med 71 (1969): 1089-95
- Lyman C, Walsh T "Systemically administered antifungal agents." Drugs 44 (1992): 9-35
- Struijk D, Krediet R, Boeschoten E, Rietra JG, Arisz L "Antifungal treatment of candida peritonitis in continuous ambulatory peritoneal dialysis patients." Am J Kidney Dis 9 (1987): 66-70
- "Product Information. Fungizone (amphotericin B)." Bristol-Myers Squibb, Princeton, NJ.
- American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
- Maddux M, Barriere S "A review of complications of amphotericin B therapy: recommendations for prevention and management." Drug Intell Clin Pharm 14 (1980): 177-81
Fungizone For Tissue Culture (amphotericin b) drug Interactions
There are 208 drug interactions with Fungizone For Tissue Culture (amphotericin b)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.